Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DCUN1D1 | Q96GG9 | 2/20 | 0.47 |
| ▸ | UBE2M | P61081 | 1/20 | 0.47 |
| ▸ | GCGR | P47871 | 18/20 | 0.47 |
| ▸ | GIPR | P48546 | 8/20 | 0.47 |
| ▸ | GLP1R | P43220 | 2/20 | 0.42 |
| ▸ | GCG | P01275 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2644538 | 0.86 | GCGR (0.56) | GCGRGIPRGLP1RGCG | |
| SCHEMBL2644011 | 0.85 | GCGR (0.59) | DCUN1D1UBE2MGCGRGIPRGLP1R | |
| SCHEMBL2644132 | 0.82 | GCGR (0.54) | DCUN1D1UBE2MGCGRGIPRGLP1R | |
| SCHEMBL9071407 | 0.81 | GCGR (0.70) | DCUN1D1UBE2MGCGRGIPRGLP1R | |
| SCHEMBL2643535 | 0.78 | GCGR (0.43) | GCGRGIPRGLP1RGCG | |
| SCHEMBL2643452 | 0.78 | GCGR (0.43) | GCGRGIPRGLP1RGCG | |
| SCHEMBL2643451 | 0.78 | GCGR (0.43) | GCGRGIPRGLP1RGCG | |
| SCHEMBL2643870 | 0.78 | GCGR (0.43) | GCGRGIPRGLP1RGCG | |
| SCHEMBL2643714 | 0.78 | GCGR (0.43) | GCGRGIPRGLP1RGCG | |
| SCHEMBL2643414 | 0.78 | GCGR (0.43) | GCGRGIPRGLP1RGCG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030203946-A1 | Glucagon antagonists/inverse agonists | NOVO NORDISK A/S (DK) | 2003-10-30 | — | — | US | disclosed |
| US-20030203946-A1 | Glucagon antagonists/inverse agonists | NOVO NORDISK A/S (DK) | 2003-10-30 | — | — | US | disclosed |
| WO-2002040445-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2002-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203946-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | DCUN1D1 2012/4885UBE2M 4517/4885GCGR 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.